|
Re: EASD 2019 Sept 16-20, 2019
|
1
|
Resverlogix Corp.
|
Jul 19, 2019 10:00AM
|
|
Re: Resverlogix Announces Publication on Apabetalone in Clinical Epigenetics
|
2
|
Resverlogix Corp.
|
Jul 15, 2019 06:53PM
|
|
Re: New Apabetalone Publication in Clinical Epigenetics
|
3
|
Resverlogix Corp.
|
Jul 12, 2019 05:58PM
|
|
Re: Insider Selling
|
2
|
Resverlogix Corp.
|
Jul 12, 2019 08:28AM
|
|
Re: I am asking myself....
|
6
|
Resverlogix Corp.
|
Jul 11, 2019 07:51PM
|
|
Re: Patient Years & MACE rate Question
|
3
|
Resverlogix Corp.
|
Jul 11, 2019 10:15AM
|
|
Re: Patient Years & MACE rate Question
|
1
|
Resverlogix Corp.
|
Jul 11, 2019 09:16AM
|
|
How does it work,... MACE after April 18, 2019
|
1
|
Resverlogix Corp.
|
Jul 09, 2019 07:37AM
|
|
Re: Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits
|
3
|
Resverlogix Corp.
|
Jul 08, 2019 04:27PM
|
|
Re: Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits
|
|
Resverlogix Corp.
|
Jul 08, 2019 12:49PM
|
|
Re: Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits
|
2
|
Resverlogix Corp.
|
Jul 08, 2019 09:11AM
|
|
Re: ESC 2019 Symposium: Epigenetics: A new pathway to tackle residual risk?
|
2
|
Resverlogix Corp.
|
Jul 06, 2019 05:38AM
|
|
We could get news any day now,....
|
2
|
Resverlogix Corp.
|
Jul 04, 2019 05:44PM
|
|
Re: Could BETonMACE Cognition Sub-Study be presented at AAIC this month?
|
3
|
Resverlogix Corp.
|
Jul 03, 2019 03:10PM
|
|
Re: Could BETonMACE Cognition Sub-Study be presented at AAIC this month?
|
2
|
Resverlogix Corp.
|
Jul 03, 2019 01:41PM
|
|
Re: No ESC 2019 Late Breaker
|
1
|
Resverlogix Corp.
|
Jul 02, 2019 10:32AM
|
|
Re: No ESC 2019 Late Breaker
|
1
|
Resverlogix Corp.
|
Jul 01, 2019 09:37PM
|
|
Re: RRR %
|
1
|
Resverlogix Corp.
|
Jul 01, 2019 12:42PM
|
|
Re: RRR %
|
1
|
Resverlogix Corp.
|
Jul 01, 2019 09:32AM
|
|
RRR %
|
4
|
Resverlogix Corp.
|
Jul 01, 2019 05:35AM
|
